ABVC BioPharma, Inc. ABVC NASDAQ

ABVC BioPharma, Inc. (ABVC) reported total assets of $21.06M and total liabilities of $7.76M for fiscal year 2025, resulting in total equity of $13.3M.

The company held $745.83K in cash and short-term investments. Total debt stood at $3.47M, with net debt of $2.79M. The Debt-to-Equity (D/E) ratio was 0.26 (conservative).

Current ratio is 0.41, which may signal tight short-term liquidity. Interest coverage is -17.2x (weak).

Criteria supported by this page:

• HEALTH (33/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (50/100) — Total assets $21.06M and equity $13.3M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.26 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 42/100 with 2/7 criteria passed.

FBRX

Forte Biosciences, Inc.

$32.42

+5.95%

MNPR

Monopar Therapeutics Inc.

$57.92

+3.28%

ELDN

Eledon Pharmaceuticals, Inc.

$3.20

-0.62%

NTRB

Nutriband Inc.

$4.06

+2.01%

ALRN

Aileron Therapeutics, Inc.

$2.11

+9.33%

MGTA

Magenta Therapeutics, Inc.

$0.70

-7.74%

SABS

SAB Biotherapeutics, Inc.

$3.86

-1.03%

RNXT

RenovoRx, Inc.

$1.03

+0.98%